The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF-κB Inactivation, and DNA Damage..